EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SARS-CoV-2 Spike Protein and Long COVID—Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome

Bruno Pereira de Melo iD, Jhéssica Adriane Mello da Silva iD, Mariana Alves Rodrigues iD, Julys da Fonseca Palmeira iD, Felipe Saldanha-Araujo iD, Gustavo Adolfo Argañaraz iD, Enrique Roberto Argañaraz iD

Viruses · 2025

DOI: 10.3390/v17050617 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Bruno Pereira de Melo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Neurovirology, Department of Pharmacy, Faculty of Health Science, University of Brasília, Brasilia 70910-900, DF, Brazil. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 infection has resulted in more than 700 million cases and nearly 7 million deaths worldwide. Although vaccination efforts have effectively reduced mortality and transmission rates, a significant proportion of recovered patients—up to 40%—develop long COVID syndrome (LC) or post-acute sequelae of COVID-19 infection (PASC). LC is characterized by the persistence or emergence of new symptoms following initial SARS-CoV-2 infection, affecting the cardiovascular, neurological, respiratory, gastrointestinal, reproductive, and immune systems. Despite the broad range of clinical symptoms that have been described, the risk factors and pathogenic mechanisms behind LC remain unclear. This review, the first of a two-part series, is distinguished by the discussion of the role of the SARS-CoV-2 spike protein in the primary mechanisms underlying the pathophysiology of LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusCOVID-19SARS-CoV-2HumansPost-Acute COVID-19 Syndrome

Stichwörter der Autor:innen

long COVID syndromepathophysiological mechanismsspike protein

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Laboratory of Molecular Neurovirology, Department of Pharmacy, Faculty of Health Science, University of Brasília, Brasilia 70910-900, DF, Brazil.
  • Laboratory of Hematology and Stem Cells (LHCT), Faculty of Health Sciences, University of Brasília, Brasilia 70910-900, DF, Brazil.

ORCID-Profile: Bruno Pereira de Melo, Jhéssica Adriane Mello da Silva, Mariana Alves Rodrigues, Julys da Fonseca Palmeira, Felipe Saldanha-Araujo, Gustavo Adolfo Argañaraz, Enrique Roberto Argañaraz

Zitieren

APA

de Melo, B. P., da Silva, J. A. M., Rodrigues, M. A., Palmeira, J. D. F., Saldanha-Araujo, F., Argañaraz, G. A., & Argañaraz, E. R. (2025). SARS-CoV-2 Spike Protein and Long COVID—Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome. Viruses. https://doi.org/10.3390/v17050617

Vancouver

de Melo BP, da Silva JAM, Rodrigues MA, Palmeira JDF, Saldanha-Araujo F, Argañaraz GA, et al. SARS-CoV-2 Spike Protein and Long COVID—Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome. Viruses. 2025. doi:10.3390/v17050617

BibTeX
@article{deMelo2025,
  author = {de Melo, Bruno Pereira and da Silva, Jhéssica Adriane Mello and Rodrigues, Mariana Alves and Palmeira, Julys da Fonseca and Saldanha-Araujo, Felipe and Argañaraz, Gustavo Adolfo and Argañaraz, Enrique Roberto},
  title = {SARS-CoV-2 Spike Protein and Long COVID—Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17050617}
}
Kostenlos starten →